What is the outlook for the Medibank dividend in FY23?

How good will the FY23 payout be from Australia's biggest private health insurer?

| More on:
A male doctor and a woman in scrubs in the foreground smile.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Medibank paid a sizeable dividend in FY22 of 13.4 cents per share
  • There are projections Medibank could pay a bigger dividend in FY23 and FY24 of 15.2 cents per share and 15.8 cents per share, respectively
  • Medibank is predicting policyholder growth in FY23

The Medibank Private Limited (ASX: MPL) dividend might be attractive for some investors focused on investment income.

Medibank is the largest private health insurer in Australia, giving it good scale benefits. This enables it to make a good profit and pay attractive dividends.

Firstly, let's look at Medibank's dividend from FY22.

FY22 dividend recap

In the FY22 result, Medibank's board decided to declare a final dividend of 7.3 cents per share. This was an increase of 5.8% year over year.

Overall, the business saw group net profit after tax (NPAT) fall 10.7% to $393.9 million due to net investment income falling from a $120 million gain in FY21 to a $24.8 million loss in FY22. However, the operating profit rose 12.5% to $594.1 million in FY22.

The full-year dividend was 13.4 cents per share, representing an increase of 5.5% compared to FY21.

Medibank's full-year dividend represented a payout ratio of 84.8% of underlying NPAT, normalising for investment market returns. This was at the top end of its target payout ratio range of between 75% to 85%.

At the current Medibank share price, this means it has an FY22 grossed-up dividend yield of 5.5%.

How big is the Medibank dividend expected to be in FY23?

Different analysts have different estimates for how much profit and how big the dividend may be from Medibank in the next couple of financial years.

For example, using the estimates on CMC Markets, Medibank is expected to generate earnings per share (EPS) of 18.4 cents in FY23 and 19.1 cents per share in FY24. This could translate into a dividend per share of 15.2 cents per share in FY23 and 15.8 cents per share in FY24. In percentage terms, this could mean a grossed-up dividend yield of 6.25% in FY23 and 6.5% in FY24.

Those dividend yields are pretty sizeable and would be attractive in my opinion. It could be a useful yield in this uncertain economic climate.

Let's have a look at a couple of the other estimates.

The broker Citi, which rates Medibank as a buy, thinks that Medibank could pay a grossed-up dividend yield of 6.5% in FY23 and 6.7% in FY24.

However, there are other estimates that put future dividends at a lower level. For example, Ord Minnett has projected that Medibank could pay a grossed-up dividend yield of 6.2% in FY23 followed by a grossed-up dividend yield of 6.6% in FY24.

Foolish takeaway

The private health insurer could generate a higher profit in FY23 with policyholder growth (projected by the company to be 2.7% in FY23). There could also be productivity improvements relating to management expenses and targeted organic or 'inorganic' growth. It's also possible that its investments could deliver gains again in FY23.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Mesoblast just cleared a key FDA hurdle. So why are investors exiting?

Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product.

Read more »

Man leaps as he runs along the street.
Healthcare Shares

ASX 300 stock jumps 6% on strong half-year results and cash flow surge

Let's see how this medical device company performed during the first half.

Read more »

Two boys lie in the grass arm wrestling.
Healthcare Shares

Is CSL or Sonic Healthcare the smarter ASX healthcare share buy?

This ASX heavyweight has potential to deliver superior returns but is more volatile.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Up more than 800% in a year. Why this ASX medical tech stock just hit an all-time high

4DMedical shares have surged over 800% as US hospital adoption and FDA clearance drive momentum.

Read more »

A retiree relaxing in the pool and giving a thumbs up.
Healthcare Shares

1 ASX dividend stock down 36% I'd buy right now

This business looks like it’s priced too cheaply.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Why investors are watching this ASX healthcare stock

A fresh clinical update has been released.

Read more »

A Sonic Healthcare medical researcher wearing a white coat sits at her desk in a laboratory conducting a COVID-19 test
Healthcare Shares

This biotech is up more than 20% on new deal news

Revenue will flow under this global deal just announced.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

The next 3 years could be huge for this ASX healthcare stock. Here's why

Today's update has put this ASX healthcare stock back in the spotlight as investors reassess its long-term growth potential.

Read more »